熱門資訊> 正文

AVITA Medical任命Cary Vance为临时首席执行官

2025-10-17 14:09

AVITA Medical (NASDAQ: NASDAQ:RCEL) announced on Thursday that the board appointed Chairman of the Board Cary Vance as Interim CEO, effective immediately.
The board plans to engage an executive search firm to assist with selecting a permanent CEO.
The company expected initial revenue to be approximately $17M for Q3 ended September 30, 2025.
Following the company’s credit agreement with OrbiMed, the company has been granted a waiver for the third quarter 2025 trailing 12-month net revenue covenant and is in discussions with OrbiMed to redefine future covenants.

More on AVITA Medical

AVITA Medical: Reimbursement Reset And Breakeven Path By 2026
AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AVITA Medical: Green Shoots Peaking Out From Hard Clay
Avita Medical stock jumps 10% after securing CE Mark for RECELL GO
Avita projects $76M–$81M 2025 revenue with rebound expected as claims backlog eases

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。